Board of Directors
Dr. van de Winkel is Chairman of the Board of Directors of Hookipa. He is also co-founder of Genmab, having served as President, Research & Development and Chief Scientific Officer (CSO) of the company until his appointment as President and Chief Executive Officer (CEO) in 2010. Prior to Genmab, Jan served as Vice President (VP) and Scientific Director of Medarex Europe. During his 25 years in the therapeutic antibody field, he has authored over 300 scientific publications and has been responsible for more than 70 patents and pending patent applications. Jan is a Professorship of Immunotherapy at Utrecht University in The Netherlands. His other roles of seniority include: member of the Board of Directors of Celdara Medical and LEO Pharma, member of the Scientific Advisory Board of Thuja Capital Healthcare Fund, and member of the Advisory Board of Capricorn Health-tech Fund. Jan holds MS and PhD degrees from the University of Nijmegen in The Netherlands.
Paul-Henri Lambert is a Non-Executive Director of the Board of Directors of Hookipa. He is senior advisor and retired professor within the Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva. He is directing the International Advanced Course of Vaccinology (ADVAC). In addition, he is also a member of the Governing Board of the Tuberculosis Vaccine Initiative (TBVI) and past-chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS) and of the WHO GACVS (Global Advisory Committee on Vaccine Safety). He was chief of Microbiology and Immunology and of Vaccine Research and Development at the World Health Organization and was deeply involved in the coordination of research aiming at the development of vaccines against diseases of major importance. Paul-Henri Lambert is author of over 430 publications, several books, member of several international Scientific Boards, foreign member of the Royal Academy of Medicine in Belgium and Fellow of the American Association for the Advancement of Science.
Dr. Christoph Lengauer is a Non-Executive Director of the Board of Directors of Hookipa. Christoph has an outstanding track record in cancer drug discovery, having contributed to the development of more than 20 medicines that reached human clinical trials and 4 that are now FDA-approved. He is currently a Venture Partner at Third Rock Ventures and President at Celsius Therapeutics, Cambridge, USA. Previously, Dr. Lengauer was Chief Scientific Officer (CSO) and Chief Drug Hunter at Blueprint Medicines, Vice President (VP) and Global Head of Oncology Drug Discovery and Preclinical Development at Sanofi and Executive Director and Senior Unit Head of Oncology Discovery at the Novartis Institutes for Biomedical Research. Prior to Novartis, Dr. Lengauer was an Associate Professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine. His research involved the discovery that all cancers are genetically unstable, and the identification of several cancer driver genes. Dr. Lengauer has authored more than 100 scientific articles which were published in leading peer reviewed scientific journals, including Cell, Nature, and Science. Christoph is an advocate for patients’ rights and was featured in the New York Times best seller and HBO movie The Immortal Life of Henrietta Lacks.
Julie O’Neill is a Non-Executive Director of the Board of Directors of Hookipa. She joins Hookipa from Alexion Pharmaceuticals, Inc. where she was Executive Vice President of Global Operations from 2015. Prior to this she was Senior Vice President of Global Operations and General Manager for Ireland at Alexion. Before joining Alexion Pharmaceuticals, Inc., Ms. O’Neill was Vice President of Operations and General Manager for Ireland at Gilead Sciences Limited where she established the Company’s Irish subsidiary and manufacturing operations and held a number of other cross-functional global leadership roles. Ms. O’Neill holds a BSc in Pharmacy from Trinity College, Dublin and an MBA from University College Dublin.
Graziano Seghezzi is a Non-Executive Director of the Board of Directors of Hookipa. He is Managing Partner at Sofinnova Partners which he joined in 2006. He invested and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on NASDAQ in 2013 and was then sold to AstraZeneca later that year. Graziano also invested and is on the Board of Mission Therapeutics (United Kingdom), Crescendo Biologics (United Kingdom) and Hookipa (Austria). He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands).
Sander van Deventer is a Non-Executive Director of the Board of Directors of Hookipa. Sander played a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). He currently is a Managing Partner at Forbion Capital Partners and Professor of Translational Gastroenterology Leiden University Medical Center. He is a member of the Boards of Argos Therapeutics (Durham, USA), uniQure (Amsterdam, The Netherlands), Hookipa (Vienna, Austria), Staten Biotechnology (Naarden, The Netherlands) and enGene (Montreal, Canada). He was trained as an internist and board certified gastroenterologist, received a doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT; now uniQure), a gene therapy company that develops adeno associated virus-based gene therapy products. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. He has authored more than 500 peer review scientific papers, and supervised more than 40 PhD students.